A Single-Center Randomized Controlled Study of Henagliflozin Proline in the Treatment of CKD Patients.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072886

Enrollment

Unknown

Registered

2023-06-27

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Control group:Salutan+symptomatic treatment

test group:Hengge Cyrity+symptomatic treatment

Chinese medicine group:Yellow Kwai Capsule+symptomatic treatment treatment

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: ? Clinical and pathological information is complete; ? Age 18-75 years old; ? Hypertension, severe infection, water, electrolyte, and acid -base balance disorders are effectively controlled, of which blood potassium is within the normal range.

Exclusion criteria

Exclusion criteria: Eliminate standards: ? Combined other glomerular diseases; ? Patients with serious diseases such as heart, brain, lung, blood system and other serious diseases; ? Women in pregnancy or lactation; ?The person with incomplete information. ? According to the judgment of researchers, those who believe should not be selected.

Design outcomes

Primary

Measure	Time frame
24-hour urinary protein quantity;	—

Secondary

Measure	Time frame
routine urine;urinary albumin/creatinine ratio,UACR;Kidney ultrasound;Renal function;	—

Countries

China

Contacts

Public ContactChen Hongyu

Hangzhou Hospital of Traditional Chinese Medicine

hzchenhy@126.com+86 157 0006 7201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026